Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway?
- 1 November 1999
- journal article
- Published by Elsevier in Pharmaceutical Science & Technology Today
- Vol. 2 (11) , 441-449
- https://doi.org/10.1016/s1461-5347(99)00211-4
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Early Phase Tumor Accumulation of Macromolecules: A Great Difference in Clearance Rate between Tumor and Normal TissuesJapanese Journal of Cancer Research, 1998
- Gene directed enzyme prodrug therapy for cancerAdvanced Drug Delivery Reviews, 1997
- The design and development of DaunoXome® for solid tumor targeting in vivoAdvanced Drug Delivery Reviews, 1997
- IntroductionAnti-Cancer Drugs, 1996
- Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's SarcomaThe Journal of Clinical Pharmacology, 1996
- Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrierEuropean Journal Of Cancer, 1995
- A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or lightJournal of Biomaterials Science, Polymer Edition, 1994
- Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N- (2-hydroxypropyl) methacrylamide copolymersJournal of Controlled Release, 1991
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990
- Structure and properties of pharmacologically active polymersJournal of Polymer Science: Polymer Symposia, 1975